Introduction Malignant pleural mesothelioma (MPM) has limited treatment options and a
poor outcome. Programmed death 1/programmed death ligand 1 (PD-L1) checkpoint …

Introduction We examined the long-term efficacy and safety of nivolumab, a human
monoclonal antibody that inhibits interactions between the programmed cell death protein-1 …

Purpose: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with
poor prognosis. Patients with MPM who do not respond to standard first-line chemotherapy …

Background In the randomized phase 3 CheckMate 743 study (NCT02899299), NIVO+ IPI
significantly prolonged overall survival (OS) vs chemo in pts with unresectable MPM. Here …

Platinum-based chemotherapy is commonly used as the standard first-line treatment for
unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune …

Introduction Dual immune checkpoint blockers regimen represents a standard first-line
therapy in unresectable pleural mesothelioma (PM). Novel combination strategies, including …

Malignant pleural mesothelioma (MPM) is a rare, locally invasive, and highly aggressive
cancer originating from the serosal surface of the pleura. Radical surgery, as a part of …

Abstract Objectives Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is a new first-line
treatment combination for patients with pleural mesothelioma. Nivolumab-ipilimumab …

The FDA approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-
line treatment of adult patients with unresectable malignant pleural mesothelioma. The …

The only registered systemic treatment for malignant pleural mesothelioma (MPM) is
platinum based chemotherapy combined with pemetrexed, with or without bevacizumab …